Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

5:01 PM ET 8-K
Partnership Tianci International, Inc. CIIT

Tianci International Partnership with BTC Digital Ltd.

Tianci International entered into a Memorandum of Understanding with BTC Digital Ltd. to cooperate on a crypto computing project with a target electrical load of 3 MW. BTC Digital will provide infrastructure and operational support while Tianci will be responsible for equipment procurement and funding for the phased deployment over the next twelve months.

Counterparty
BTC Digital Ltd.
Term
12 months
5:01 PM ET 8-K
Partnership Jbs N.V. JBS

Jbs Partnership with Viva Holding Ltda.

JBS S.A., a subsidiary of JBS N.V., entered into a definitive association agreement with Viva Holding Ltda. to form a 50/50 joint venture named 'JBS Viva' focused on leather production and processing. The transaction involves JBS contributing its leather division assets (excluding certain international and Texas-based plants) and Viva contributing its leather and chemical processing assets. The new entity will feature parity governance with a board composed of three members from each party.

Counterparty
Viva Holding Ltda.
4:59 PM ET 8-K
M&A Deal Forward Industries, Inc. FWDI

Forward Industries M&A Deal with SkyAI, Inc.

Forward Industries has delivered an updated non-binding proposal to acquire all outstanding shares of SkyAI, Inc. for a combination of cash and stock. The offer uses a fixed exchange ratio of 0.306 Forward shares per SkyAI share, implying a value of $2.13 per share and a 50% premium over SkyAI's recent closing price.

Counterparty
SkyAI, Inc.
Earnings call
Sep 25, 2026, 5:00 PM ET
4:59 PM ET 8-K
Regulatory Approval Beta Bionics, Inc. BBNX

Beta Bionics Regulatory Approval

Beta Bionics received FDA clearance for Mint, its next-generation patch pump featuring a reusable and disposable architecture and smartphone control. The company also submitted a 510(k) application for its 3D Intelligence insulin dosing algorithm, which is expected to power its future automated insulin delivery platforms.

“We believe that our next-generation AID platform, consisting of Mint 3D and iLet 3D, will represent a transformational advancement for people living with diabetes, subject to regulatory clearance by the FDA.”

Sean Saint, President & CEO of Beta Bionics
4:58 PM ET 8-K
Capital Raise Rent the Runway, Inc. RENT

Rent the Runway Capital Raise of $15M

Rent the Runway announced a record date of September 25, 2026, for its previously announced $15 million rights offering. The company intends to distribute transferable subscription rights to purchase up to 4,225,352 shares of Class A common stock at a subscription price of at least $3.55 per share.

Value
$15M
4:50 PM ET 8-K
M&A Deal Safety Insurance Group Inc SAFT

Safety Insurance Group M&A Deal with MAPFRE U.S.A. Corp.

Safety Insurance Group announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act expired on September 14, 2026, satisfying a key regulatory condition for its pending merger with MAPFRE U.S.A. Corp. The transaction, originally announced in July 2026, will result in Safety becoming a wholly owned subsidiary of MAPFRE. The closing remains subject to other customary conditions and additional regulatory approvals.

Counterparty
MAPFRE U.S.A. Corp.
4:46 PM ET 8-K
Nasdaq/NYSE Compliance Notice XMax Inc. XMAX

XMax Nasdaq/NYSE Compliance Notice

XMax Inc. received a deficiency notice from Nasdaq on September 10, 2026, for failing to comply with Listing Rule 5635(d) regarding shareholder approval for discounted share issuances. The company aggregated several private placements from December 2025 through April 2026 that exceeded 20% of outstanding shares at prices below the required minimum. The company has until October 26, 2026, to submit a plan to regain compliance and avoid potential delisting.

Counterparty
Nasdaq Stock Market LLC
Term
45 days to submit plan
4:31 PM ET 8-K
M&A Deal Flag Ship Acquisition Corp FSHP

Flag Ship Acquisition Signs $400M M&A Deal with Bluechip & Co. Holdings

Flag Ship Acquisition Corporation (SPAC) has entered into a definitive merger agreement to acquire Bluechip & Co. Holdings, a provider of insurance-related customer acquisition and AI-driven data services. The transaction values Bluechip at an aggregate net value of $400 million, with the consideration consisting of 40,000,000 ordinary shares of the surviving entity. Upon closing, Bluechip will become a wholly owned subsidiary of a new publicly traded parent company.

Value
$400M
Counterparty
Bluechip & Co. Holdings
4:17 PM ET 8-K/A
Bankruptcy & Restructuring New Fortress Energy Inc. NFE

New Fortress Energy Bankruptcy & Restructuring

New Fortress Energy completed a comprehensive restructuring of its principal funded debt obligations via UK restructuring plans sanctioned by the High Court of Justice. The transaction involved separating the company into two independent entities (BrazilCo and CoreCo) and exchanging existing debt for equity in BrazilCo, $571.3 million in new senior secured term loans, and Series A convertible preferred stock.

Counterparty
High Court of Justice of England and Wales
4:09 PM ET 8-K
Capital Raise Grayscale Bittensor Trust (TAO) GTAO

Grayscale Bittensor Trust Capital Raise of $651K

Grayscale Bittensor Trust (TAO) issued 148,800 shares to accredited investors in private placement transactions for an aggregate of 2,814.13415038 TAO, valued at approximately $650,589. The shares were issued at varying prices based on the Trust's NAV per share, bringing the total shares outstanding to 2,842,300 as of September 15, 2026.

Value
$651K
Counterparty
Accredited investors
4:07 PM ET 8-K
Capital Raise Tempest Therapeutics, Inc. TPST

Tempest Therapeutics Capital Raise of $2.5M

Tempest Therapeutics entered into a securities purchase agreement with an institutional investor for a private placement of pre-funded warrants and accompanying Series C and D warrants. The company raised approximately $2.5 million in gross proceeds, with the potential for an additional $5 million upon the cash exercise of the common warrants. Proceeds are intended for working capital and general corporate purposes.

Value
$2.5M
Counterparty
institutional investor
4:06 PM ET 8-K
Capacity Expansion Applied Optoelectronics, Inc. AAOI

Applied Optoelectronics Capacity Expansion

Applied Optoelectronics' subsidiary, Global Technology, Inc., entered into a 10-year lease for a 38,311.8 square meter factory building in Ningbo, China. The company intends to make alterations and improvements to the property to accommodate its production requirements. The lease includes a three-month rent-free renovation period and a right of first refusal to purchase the property.

Counterparty
Ningbo Yiduofu Industrial Co., Ltd.
Term
10 years
4:06 PM ET 8-K
Divestiture Zoned Properties, Inc. ZDPY

Zoned Properties Divestiture to BPB Partners, LLC

Stockholders of Zoned Properties, Inc. approved the sale of substantially all of the company's assets to BPB Partners, LLC, an entity owned by members of the company's management group. The transaction, structured as a management buy-out (MBO), received both majority and disinterested stockholder approval at a special meeting held on September 11, 2026. Stockholders also approved, on an advisory basis, the compensation arrangements for named executive officers related to the asset sale.

Counterparty
BPB Partners, LLC
4:06 PM ET 8-K
Research Collaboration Co-Diagnostics, Inc. CODX

Co-Diagnostics Research Collaboration with ReadyGo Diagnostics Ltd

Co-Diagnostics entered into a material transfer agreement with ReadyGo Diagnostics Ltd to evaluate the compatibility of ReadyGo's sample collection and preparation technologies with the Co-Dx PCR platform. The collaboration involves feasibility studies and compatibility testing to potentially streamline the sample-to-result workflow for decentralized and point-of-care testing. The agreement is preliminary and does not obligate either party to enter into a formal commercial or development arrangement.

Counterparty
ReadyGo Diagnostics Ltd
4:05 PM ET 8-K
M&A Deal Harte Hanks Inc HHS

Harte Hanks Signs $19.2M M&A Deal with Star Equity Holdings, Inc.

Harte Hanks announced the expiration of the 'Go-Shop Period' under its existing merger agreement with Star Equity Holdings, Inc. During this period, the company solicited 93 third parties and received alternative acquisition proposals, leading to the designation of certain 'Exempted Parties' for further discussion. However, the Board has not yet determined any proposal to be superior and currently reaffirms its recommendation for the Star merger, which includes a $19.2 million cash consideration cap.

Value
$19.2M
Counterparty
Star Equity Holdings, Inc.
3:57 PM ET 8-K
M&A Deal Curaleaf Holdings, Inc. CURLF

Curaleaf Holdings M&A Deal with Aurora Cannabis Inc.

Curaleaf Holdings, Inc. issued a letter to shareholders of Aurora Cannabis Inc. urging them to accept its acquisition offer, which represents a 45% premium over Aurora's 30-day VWAP. The proposed combination would create a global cannabis leader with operations in 17 countries and approximately $1.5 billion in combined LTM revenue.

Counterparty
Aurora Cannabis Inc.
3:51 PM ET 8-K
Nasdaq/NYSE Compliance Notice Sobr Safe, Inc. SOBR

Sobr Safe Nasdaq/NYSE Compliance Notice

SOBR Safe, Inc. received a delisting notice from Nasdaq on September 14, 2026, notifying the company that its common stock will be delisted at the open of trading on September 16, 2026. The company failed to regain compliance with the $1.00 minimum bid price requirement and the minimum stockholders' equity requirement by the September 15, 2026 deadline previously set by the Nasdaq Hearings Panel. The delisting follows a series of cumulative reverse stock splits exceeding a 1-for-250 ratio, which made the company ineligible for standard compliance grace periods.

Counterparty
Nasdaq Stock Market LLC
11:30 AM ET 8-K
M&A Deal Invech Holdings, Inc. IVHI

Invech Holdings M&A Deal with Angel Javier Perez Jimenez

Angel Javier Perez Jimenez acquired a controlling interest in Invech Holdings, Inc. from Stephen Ken Adair for an aggregate price of $291,390. The transaction involved the purchase of 88,000,000 common shares and 300,000 Series A Preferred shares, resulting in a change of control and the appointment of Perez Jimenez as the sole director and executive officer.

Counterparty
Angel Javier Perez Jimenez
10:53 AM ET 8-K
M&A Deal JLL Income Property Trust, Inc. ZIPTAX

JLL Income Property Trust Signs $19M M&A Deal with Roseville Outpatient Center

JLL Income Property Trust acquired the Roseville Outpatient Center, a 42,000-square-foot Class A medical facility in the Sacramento area, for approximately $19 million. The property is 95% leased and was fully redeveloped in 2024, strengthening the company's healthcare portfolio which now totals $667 million across 26 properties.

Value
$19M
Counterparty
Roseville Outpatient Center
Term
12-year weighted average lease term
10:45 AM ET 8-K
M&A Deal Launch Two Acquisition Corp. LPBB

Launch Two Acquisition M&A Deal with NuCube Energy, Inc.

Launch Two Acquisition Corp. and NuCube Energy, Inc. announced the public filing of a registration statement on Form S-4 with the SEC regarding their previously announced business combination. The filing is a key regulatory step toward closing the merger, which will result in NuCube becoming a publicly traded company. The transaction remains subject to shareholder approval and other customary closing conditions.

Counterparty
NuCube Energy, Inc.
10:19 AM ET 8-K
Partnership LifeMD, Inc. LFMD

LifeMD Partnership with AT&T Services, Inc.

LifeMD entered into an exclusive strategic collaboration with AT&T to provide complimentary LifeMD memberships to over 100 million eligible AT&T wireless and fiber customers. The partnership involves a multi-phase nationwide rollout and the establishment of a joint steering committee to oversee marketing, pricing, and performance.

Counterparty
AT&T Services, Inc.
Term
1 year
10:09 AM ET 8-K
M&A Deal RTB Digital, Inc. RTB

RTB Digital Announces $10M M&A Deal

RTB Digital (Roundtable) announced it has signed a definitive agreement for a transformative merger transaction, previously disclosed as a $10 million deposit. CEO James Heckman will host a shareholder call on September 17, 2026, to discuss the deal's impact on the company's revenue trajectory, audience scale, and financial forecast.

Value
$10M
Earnings call
Sep 17, 2026, 11:00 AM ET
9:28 AM ET 8-K
Capital Raise Healthstream Inc HSTM

Healthstream Capital Raise of $40M

HealthStream completed a $40 million private placement of 1,355,932 newly issued shares of common stock to WJRJJ Ventures, LLC at $29.50 per share. Simultaneously, CEO Robert A. Frist, Jr. sold an additional 144,068 shares to the same investor for $4.25 million. The company intends to use the proceeds for general corporate purposes, including potential acquisitions and strategic initiatives.

Value
$40M
Counterparty
WJRJJ Ventures, LLC
9:26 AM ET 8-K
Capital Raise Dream Finders Homes, Inc. DFH

Dream Finders Homes Capital Raise of $225M

Dream Finders Homes, Inc. entered into subscription agreements with institutional investors to sell 225,000 shares of newly-created Series B Convertible Preferred Stock for $225 million. The proceeds were used to redeem existing Series A Preferred Stock, with a second closing of $450 million contingent upon the completion of the company's pending merger with Beazer Homes USA, Inc.

Value
$225M
Counterparty
institutional investors
9:07 AM ET 8-K
M&A Deal Jazz Pharmaceuticals plc JAZZ

Jazz Pharmaceuticals Signs $820M M&A Deal with Actio Biosciences, Inc.

Jazz Pharmaceuticals completed its acquisition of Actio Biosciences for $820 million upfront, making Actio a wholly-owned subsidiary. The deal adds ABS-1230, a clinical-stage precision therapy for KCNT1-related epilepsy, to Jazz's rare disease and epilepsy pipeline. As part of the transaction, Actio spun out its non-ABS-1230 programs into a new private entity in which Jazz retains a minority stake.

Value
$820M
Counterparty
Actio Biosciences, Inc.
9:01 AM ET 8-K
M&A Deal 5E Advanced Materials, Inc. FEAM

5E Advanced Materials M&A Deal with Searles Valley Minerals Inc.

5E Advanced Materials has entered into a definitive asset purchase agreement to acquire the operating assets of Searles Valley Minerals through a Section 363 bankruptcy sale process. The acquisition includes critical mineral production facilities, 9,000 acres of brine resources, and integrated infrastructure in California, transforming 5E from a pre-revenue developer into an active producer of borates and boric acid. Consideration for the deal consists of $3.4 million in cash, 8.3 million shares of common stock, and a $6.2 million senior unsecured promissory note.

Counterparty
Searles Valley Minerals Inc.
8:58 AM ET 8-K
Capital Raise GT Biopharma, Inc. GTBP

GT Biopharma Capital Raise of $7.45M

GT Biopharma entered into a securities purchase agreement for a private placement of up to 8,277.778 shares of Series M 10% Convertible Preferred Stock and associated warrants for an initial purchase price of $7.45 million. The agreement includes 'Greenshoe Rights' allowing purchasers to acquire additional preferred stock with a stated value of up to $33.33 million for an additional $30 million. The preferred stock is convertible into common stock at an initial conversion price of $6.10 per share.

Value
$7.45M
8:55 AM ET 8-K
Clinical Trial Data Pulse Biosciences, Inc. PLSE

Pulse Biosciences Clinical Trial Data

Pulse Biosciences announced the completion of patient enrollment in its PRECISE-BTN clinical study, which evaluated the nPulse Vybrance Percutaneous Electrode System for treating symptomatic benign thyroid nodules. The study was expanded from 50 to 100 patients across three U.S. sites, and the first patient has already completed the final 12-month follow-up visit. Preliminary data is expected to be presented at an upcoming medical conference.

8:45 AM ET 8-K
Clinical Trial Data Summit Therapeutics Inc. SMMT

Summit Therapeutics Clinical Trial Data

Summit Therapeutics announced updated overall survival (OS) results from its global Phase III HARMONi trial of ivonescimab in patients with EGFR-mutated non-small cell lung cancer. The updated June 2026 analysis showed a favorable OS hazard ratio of 0.76 in the global population, demonstrating consistent efficacy across both Western and Asian patient subgroups. No new safety signals were observed, reinforcing the potential of ivonescimab as a treatment option following progression on EGFR-targeted therapy.

Counterparty
Akeso Inc.
8:31 AM ET 8-K
Regulatory Approval Scholar Rock Holding Corp SRRK

Scholar Rock Holding Regulatory Approval

Scholar Rock announced that the FDA has approved ISEMBYLD (apitegromab-mstn) for the treatment of spinal muscular atrophy in adults and children 2 years of age and older. The filing also clarifies that the approval includes a post-marketing requirement for a pregnancy safety study and a request for alert reports regarding bone fractures.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.